EBS: Emergent BioSolutions Inc. - Summary | Jitta

Emergent BioSolutions Inc.

NYSE:EBS

Price
$62.71
Loss Chance
44.0%
5.90JITTA SCORE
70.35%Under Jitta Line
Jitta Ranking
4 / 1,041
183 / 4,594
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (73)
Recent Business Performance (96)
Financial Strength (78)
Return to Shareholders (34)
Competitive Advantage (74)
Jitta Signs
Revenue and EarningConsistent High Growth in the past 3 years
Recent Business PerformanceEarning Growth Last Year
Interest Coverage RatioVery Good
SG&A to SalesDecreasing
Operating MarginInconsistent
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
5.90
70.35%
1.43
197.95%
2.25
348.40%
Biotechnology
6.28
43.68%
4.83
30.68%
5.85
26.32%
COMPANY DESCRIPTION
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company’s products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; and Trobigard a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG potential treatments to COVID-19 disease; and FLU-IGIV for the treatment of Influenza A infection in hospitalized patients. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing in the pharmaceutical and biotechnology industries, as well as the governments and non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.